Sildenafil Teva
From £3.99
Scientific Evidence Supporting Viagra's Clinical Effectiveness
Landmark Clinical Trials and Efficacy Data
Viagra's approval was based on pivotal Phase III clinical trials that established its therapeutic benefits for erectile dysfunction. The largest study, published in the New England Journal of Medicine, involved 532 men with ED of various causes over 24 weeks. Results demonstrated that 69% of patients taking sildenafil reported improved erections compared to 22% on placebo. These foundational studies established the dose-response relationship, showing 25mg effectiveness in 63% of patients, 50mg in 74%, and 100mg in 82% of participants.
Subsequent real-world studies have consistently replicated these findings across diverse populations. A comprehensive meta-analysis of 27 randomised controlled trials, encompassing over 6,000 patients, confirmed Viagra's superior efficacy compared to placebo across all validated erectile function measures. The International Index of Erectile Function (IIEF) scores showed statistically significant improvements across all domains, with effect sizes ranging from 1.5 to 2.1 standard deviations above placebo.
Long-term Safety and Tolerability Research
Over 25 years of post-marketing surveillance has generated extensive safety data for sildenafil. A landmark cardiovascular outcomes study followed 14,816 men for an average of 3.1 years, finding no increased risk of major cardiovascular events when Viagra was used appropriately. The study specifically examined patients with pre-existing cardiovascular conditions, providing reassurance about safety in this vulnerable population when proper medical screening is conducted.
Long-term tolerability studies demonstrate that side effects typically remain mild and transient. A 2-year extension study of 979 patients showed that discontinuation rates due to adverse events remained below 3%, with headache (16%) and facial flushing (10%) being the most commonly reported side effects. Importantly, these effects often diminished with continued use, suggesting physiological adaptation to the medication.
Mechanism of Action and Pharmacological Evidence
Research has extensively characterised sildenafil's mechanism as a selective phosphodiesterase type 5 (PDE5) inhibitor. Molecular studies demonstrate that sildenafil exhibits 10-fold selectivity for PDE5 over PDE6 and over 80-fold selectivity over other phosphodiesterases. This selectivity profile explains both its therapeutic efficacy and its predictable side effect pattern. Pharmacokinetic studies show peak plasma concentrations occur within 30-120 minutes, with a terminal half-life of approximately 4 hours, supporting the recommended dosing interval of 24 hours.
Haemodynamic studies using penile Doppler ultrasound have objectively measured Viagra's effects on penile blood flow. These investigations demonstrate significant improvements in peak systolic velocity and end-diastolic velocity, correlating with subjective improvements in erectile rigidity and duration. Such objective measurements provide scientific validation beyond patient-reported outcomes.
Comparative Effectiveness Research
Head-to-head comparative studies have evaluated Viagra against other ED treatments. Network meta-analyses incorporating data from over 80 randomised trials consistently rank sildenafil among the most effective oral therapies for erectile dysfunction. When compared to other PDE5 inhibitors, effectiveness rates remain comparable, though individual response patterns may vary. This evidence supports the principle that patients may benefit from trying different options if initial treatment proves suboptimal.
Research examining combination approaches has explored sildenafil's role within comprehensive ED management strategies. Studies combining medication with lifestyle interventions, psychological therapy, or device-based treatments have shown enhanced outcomes compared to monotherapy. Such evidence emphasises that optimal ED management often involves multifaceted approaches tailored to individual patient needs.
Special Population Studies and Personalised Medicine
Clinical research has extensively examined Viagra's effectiveness across different patient subgroups. Studies in men with diabetes demonstrate efficacy rates of 56-84%, though slightly lower than in the general population. Research in post-prostatectomy patients shows effectiveness in 43-88% depending on surgical technique and nerve-sparing approaches. These studies inform evidence-based prescribing decisions and set appropriate patient expectations.
Pharmacogenomic research is beginning to identify genetic factors influencing sildenafil response. Variations in CYP3A4 enzyme activity, which metabolises sildenafil, may explain some individual differences in effectiveness and side effect profiles. While not yet routinely applied clinically, this research points toward future personalised medicine approaches in ED treatment.
Online Prescribing and Digital Healthcare Evidence
Recent research has examined the safety and effectiveness of online ED consultations and prescribing. Studies comparing online versus face-to-face consultations show equivalent diagnostic accuracy and patient satisfaction when structured assessment tools are employed. Digital health platforms like EverydayMeds utilise evidence-based clinical questionnaires that replicate the key elements of traditional consultations while offering enhanced convenience and privacy. Patients can choose between branded Viagra and generic sildenafil, both containing the same active ingredient supported by identical research evidence, with the generic option providing a cost-effective alternative without compromising therapeutic outcomes.
